Clinical Trial

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with other NCCN-recommended standard treatments for NMIBC (gemcitabine with or without docetaxel, mitomycin, re-treatment with BCG, or pembrolizumab).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-14; most recent amendment 2026-05-07.
Trial Details
NCT Number NCT06929286
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Non-Muscle Invasive Bladder Cancer
Enrollment 125 participants
Start Date 2025-04-11
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-31